neoplasms

Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis.

Sarcopenia in gynaecologic oncology patients has garnered increasing attention, but its prevalence has not been comprehensively summarized. This study aims to integrate the prevalence of sarcopenia in this population through systematic evaluation and meta-analysis, providing a reference for future clinical...

🗓️ 2025-02-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis.

Brown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play...

🗓️ 2024-12-30
📰 Publication: Clinical Nutrition
Read MoreBrown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-κB signaling and oxidative stress play...

🗓️ 2024-04-08
📰 Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-κB signaling and oxidative stress.

Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

Metabolic reprogramming of cancer cells and the tumour microenvironment are pivotal characteristics of cancers, and studying these processes offer insights and avenues for cancer diagnostics and therapeutics. Recent advancements have underscored the impact of host systemic features, termed macroenvironment, on...

🗓️ 2025-01-20
📰 Publication: Nature Reviews Cancer
Read MoreMetabolic interplays between the tumour and the host shape the tumour macroenvironment.

Systemic metabolic crosstalk as driver of cancer cachexia.

Cachexia is a complex metabolic disorder characterized by negative energy balance due to increased consumption and lowered intake, leading to progressive tissue wasting and inefficient energy distribution. Once considered as passive bystander, metabolism is now acknowledged as a regulator of...

🗓️ 2025-01-04
📰 Publication: Trends In Endocrinology And Metabolism
Read MoreSystemic metabolic crosstalk as driver of cancer cachexia.

The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Alterations in bile acid profile and pathways contribute to hepatic inflammation in cancer cachexia, a syndrome worsening the prognosis of cancer patients. As the gut microbiota impinges on host metabolism through bile acids, the current study aimed to explore the...

🗓️ 2025-01-08
📰 Publication: Gut Microbes
Read MoreThe microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Body composition alterations in patients with lung cancer.

Most patients with lung cancer experience cancer cachexia (CC), a syndrome of skeletal muscle and adipose tissue wasting. Knowledge of body composition changes in patients is limited, however, because most studies have been cross-sectional, comparing patients with non-cancer controls or...

🗓️ 2025-01-31
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreBody composition alterations in patients with lung cancer.

Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and...

🗓️ 2025-02-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

The essential amino acid methionine plays a pivotal role in one-carbon metabolism, facilitating the production of S-adenosylmethionine (SAM), a critical supplier for DNA methylation and thereby a modulator of gene expression. Here, we report that the methionine cycle is disrupted...

🗓️ 2024-12-20
📰 Publication: Cell Metabolism
Read MoreDisrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

CT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies.

Older adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico-demographic characteristics inadequately explain this increased risk limiting accurate prognostication. Prior studies have suggested that altered body composition and frailty are independently...

🗓️ 2024-12-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies.

Comment on 'Association of Computed Tomography-Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis' by Van Helsdingen et al.

🗓️ 2025-02-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on 'Association of Computed Tomography-Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis' by Van Helsdingen et al.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...

🗓️ 2024-12-16
Read MoreClinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Targeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles.

Metastatic progression significantly reduces survival rates and complicates treatment strategies in various cancers. Our study introduces an mRNA therapy for metastasis inhibition by targeting activin A overexpression, a pivotal driver of metastasis and cachexia. Utilizing follistatin mRNA lipid nanoparticles, we...

🗓️ 2024-11-21
📰 Publication: Acs Nano
Read MoreTargeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!